The most common sources of neuropathic pain include diabetic neuropathic pain (DNP), post therapeutic neuralgia (PHN), and HIV-related neuropathic pain. These three conditions are estimated to affect over 6 million people across the seven major pharmaceutical markets (US, UK, Japan, France, Germany, Italy, and Spain ). However, the affected population expands dramatically when spinal cord injury, lower back, cancer-induced, and postoperative neuropathic pain conditions are included.
With approximately 4.7 million people suffering from neuropathy pain in the US alone (GloboData), with no viable treatment options, neuropathic pain represents an area of significant unmet medical need.The neuropathic pain market for the seven major developed countries referenced is expected to grow from US$2.4 billion in 2010 to $3.6 billion in 2020.
There are no disease-modifying or curative agents for the management of neuropathic pain. It is estimated only one in four patients with neuropathic pain experiences measurable pain relief. The pharmaceutical industry has so far struggled to improve on current therapeutic options, owing to the complexity of identifying the most appropriate targets to investigate.
Dr Riyi Shi’s pre-clinical findings to date:
- Acrolein increases in spinal cord injury (SCI)
- Acrolein injected into the spinal cord increases inflammation and causes pain (pain markers in animals) by 50-70%
- Acrolein increases post SCI
- Acrolein starts and sustains oxidative stress in SCI
- Hydralazine reduces Acrolein in SCI
- Pre-symptomatic (preventive) treatment with hydralazine reduces acute neuropathic pain in SCI
- Delayed Hydralazine treatment reduces neuropathic pain in SCI (even 5 months post-SCI)
- Hydralazine treatment reduces inflammation and oxidative stress in SCI
If high Acrolein can be clinically proven to be a factor in causing or intensifying neuropathic pain, Neuro Vigor’s Acrolein reducing strategy has the potential to be a first line treatment for neuropathic pain from multiple causes and with minimal side effects. The company intends to pursue development of such treatment(s) including companion diagnostics following initial, successful development of our MS solutions. However, properly funded and resourced, Neuro Vigor’s development of its neuropathic pain therapy(s) could be on a parallel path with its MS development program.